We then validated the scRNA‐seq results using flow cytometry to detect various immune cell types in these two tumor samples, and the results indicated a decrease in CD11b+Gr‐1+ cells (MDSCs), especially Ly6G+Ly6Clow cells (PMN‐MDSCs) within this population in the tRF‐22 knockdown group. The gene discussed is ITGAM; the disease is neoplasm.